Forma Therapeutics, Inc.

Torsten Herbertz

Shawn E R Schiller

Kenneth W Bair

Matthew W Martin

David S Millan

Adam Charles Talbot

George P Luke

Katherine J Kayser-Bricker

Goss S Kauffman

Anna M Ericsson

Steven Gregory Mischke

Hongbin Li

Angela V West

Bradford Graves

Jennifer R Downing

Mark Joseph Tebbe

Goss Stryker Kauffman

Shawn E Schiller

Shawn ER Schiller

Mark J Tebbe

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Inhibiting CREB binding protein (CBP)

The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.

Inhibiting cyclic AMP-responsive element-binding protein (CREB)

Tetrahydro-imidazo quinoline compositions as CBP/P300 inhibitors

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula I: wherein W, X, Y, Z, R, R, R, and Rare as described herein.

Tetrahydroquinoline compositions as BET bromodomain inhibitors

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R, R, Rand Rare defined herein.

Benzopiperazine compositions as BET bromodomain inhibitors

Tetrahydroquinoline compositions as bet bromodomain inhibitors

The present invention relates to inhibitors of bromo and extra terminal (BET) br'omodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein X, Y, Z, R, R, Rand Rare defined herein.

Growing community of inventors

Stow, MA, United States of America

Torsten Herbertz